IL165255A0 - A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease - Google Patents

A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease

Info

Publication number
IL165255A0
IL165255A0 IL16525503A IL16525503A IL165255A0 IL 165255 A0 IL165255 A0 IL 165255A0 IL 16525503 A IL16525503 A IL 16525503A IL 16525503 A IL16525503 A IL 16525503A IL 165255 A0 IL165255 A0 IL 165255A0
Authority
IL
Israel
Prior art keywords
nmda
antagonist
teh
alzheimer
disease
Prior art date
Application number
IL16525503A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29713304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL165255(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of IL165255A0 publication Critical patent/IL165255A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16525503A 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease IL165255A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31
PCT/DK2003/000342 WO2003101458A1 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
IL165255A0 true IL165255A0 (en) 2005-12-18

Family

ID=29713304

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16525503A IL165255A0 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease

Country Status (17)

Country Link
EP (1) EP1509232B1 (de)
JP (1) JP2005528431A (de)
AT (1) ATE414519T1 (de)
AU (1) AU2003227516B2 (de)
BR (1) BR0311375A (de)
CY (1) CY1108725T1 (de)
DE (1) DE60324788D1 (de)
DK (1) DK1509232T3 (de)
ES (1) ES2314200T3 (de)
IL (1) IL165255A0 (de)
MX (1) MXPA04011762A (de)
NO (1) NO332754B1 (de)
NZ (1) NZ536603A (de)
PL (1) PL373903A1 (de)
PT (1) PT1509232E (de)
SI (1) SI1509232T1 (de)
WO (1) WO2003101458A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20094759B (en) * 2002-10-24 2009-08-25 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
RU2371173C2 (ru) * 2004-01-05 2009-10-27 Мерц Фарма Гмбх Унд Ко. Кгаа Мемантин для лечения болезни альцгеймера легкой и от легкой до умеренной степени тяжести
JP2007518755A (ja) * 2004-01-22 2007-07-12 ノイロサーチ アクティーゼルスカブ モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US20070213388A1 (en) * 2004-03-19 2007-09-13 Bruinsma Gosse B Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists Useful in the Treatment of of Cognitive Disorders
SG157415A1 (en) * 2004-11-23 2009-12-29 Adamas Pharmaceuticals Inc Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
RU2445092C2 (ru) * 2005-04-28 2012-03-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Композиция, содержащая средство против деменции
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
BR112012019923A2 (pt) 2010-02-09 2016-08-09 Univ Johns Hopkins métodos e composições para melhorar a função cognitiva
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2590696B1 (de) 2010-07-05 2017-03-08 Gambro Lundia AB Ambulante ultrafiltriervorrichtung, zugehörige verfahren und computerprogrammprodukt
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2013160728A1 (en) * 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014035355A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Pharmaceutical combination comprising idebenone and memantine
WO2014055047A1 (en) * 2012-08-31 2014-04-10 Mahmut Bilgic Combination of idebenone and donezepil
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
GEP201706739B (en) * 2012-12-13 2017-09-25 H Lundbeck As Compositions comprising vortioxetine and donepezil
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (de) 2013-03-15 2021-05-05 Agenebio, Inc. Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
JP6629464B2 (ja) * 2016-05-18 2020-01-15 スヴェン・ライフ・サイエンシズ・リミテッド 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
WO2018081508A1 (en) * 2016-10-28 2018-05-03 Chase Pharmaceutical Corporation Memantine combinations and use
TR201619184A2 (tr) 2016-12-22 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
BR112021024054A2 (pt) 2019-05-31 2022-01-11 Tecnimede Soc Tecnico Medicinal Sa Composições farmacêuticas de combinação de dose fixa de liberação imediata, seus métodos e usos.

Also Published As

Publication number Publication date
JP2005528431A (ja) 2005-09-22
PT1509232E (pt) 2009-01-07
DK1509232T3 (da) 2009-02-23
DE60324788D1 (de) 2009-01-02
PL373903A1 (en) 2005-09-19
ATE414519T1 (de) 2008-12-15
NZ536603A (en) 2007-06-29
NO20045434L (no) 2004-12-13
WO2003101458A1 (en) 2003-12-11
MXPA04011762A (es) 2005-03-31
AU2003227516B2 (en) 2008-03-20
BR0311375A (pt) 2005-03-15
EP1509232A1 (de) 2005-03-02
SI1509232T1 (sl) 2009-04-30
NO332754B1 (no) 2013-01-07
CY1108725T1 (el) 2014-04-09
ES2314200T3 (es) 2009-03-16
AU2003227516A1 (en) 2003-12-19
EP1509232B1 (de) 2008-11-19

Similar Documents

Publication Publication Date Title
IL165255A0 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease
GB0223040D0 (en) Therapeutic compounds
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
GB0005251D0 (en) Therapeutic compounds
SI1663185T1 (sl) Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
WO1999005096A3 (en) Urokinase inhibitors
HUP0302955A3 (en) Hmg-coa reductase inhibitors, pharmaceutical compositions containing them and their use for treatment of cholesterol related diseases
AU7031500A (en) Therapeutic quinazoline compounds
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
ATE234282T1 (de) Polymorphe verbindungen
TR200101120T2 (tr) Serin proteaz inhibitörü
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
WO2003059254A3 (en) Prevention and treatment of atherosclerosis and restenosis
GB9907571D0 (en) Compounds
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
RS20050420A (en) Prevention and treatment of alzheimer's disease
SE0004827D0 (sv) Therapeutic compounds
EP0976404A3 (de) Pharmazeutische Zubereitung zur Vorbeugung und Behandlung von kognitiven Störungen bei Säugetieren
PT1276722E (pt) Inibidores de naftamidina-uroquinase
RS20050514A (en) Compounds having prolyl oligopeptidase inhibitory activity
WO2006020850A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders